Medtronic stock trades at EUR 91.88, up 0.44% premarket
Published on 11/20/2026 at 08:15 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey Takeaways for Investors
- Medtronic plans to acquire Contego Medical in a transaction valued at USD 380 million plus potential post-acquisition payments.
- The deal would add carotid and peripheral thrombectomy technologies to Medtronic's cardiovascular portfolio.
- Medtronic expects the transaction to be minimally dilutive to adjusted EPS in fiscal 2027 and fiscal 2028.
Medtronic stock traded at EUR 91.88 on Lang & Schwarz at 08:11 CET on Friday, November 20, 2026, 0.44 percent above the Xetra close of Thursday, November 19, 2026.
Contego Deal Adds Vascular Reach
In its Nov. 16 announcement, Medtronic said it intends to acquire privately held Contego Medical in a transaction valued at USD 380 million, with potential payments after closing. The deal would broaden Medtronic's portfolio in carotid artery disease and peripheral vascular disease.
The planned acquisition includes Contego's FDA-approved Neuroguard IEP Direct System, which combines transcarotid artery revascularization with integrated embolic protection and flow reversal. It also includes Excipio thrombectomy devices, which complement Medtronic's Liberant system for peripheral vascular disease.
Medtronic expects to complete the transaction in the third quarter of its fiscal year, subject to customary closing conditions. The company expects the acquisition to be minimally dilutive to adjusted earnings per share in fiscal 2027 and fiscal 2028, and neutral to accretive thereafter. For investors, the transaction adds product breadth in cardiovascular care while placing near-term emphasis on portfolio expansion rather than immediate earnings growth.
The broader US market is tracked by the S&P 500.
